---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-25-000096"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T04:56:28.948607+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Arcutis sets director cash retainers at $50k-$35k, annual equity value at $300k; all proposals at annual meeting pass

## Summary
- Cash retainers: $50k for non-employee directors; additional $35k for non-exec chair; committee chairs $20k (audit), $15k (comp), $10k (nominating).
- Equity: initial option up to $300k value for new directors; annual award ~$300k split 65% option (up to $195k) and 35% RSU (up to $105k).
- Plan amended effective June 11, 2025; board approved revisions to attract and retain qualified directors.
- Shareholders reelected directors Chaudhuri, Lin, Welgus; ratified Ernst & Young as auditor; approved non-binding say-on-pay.

## SEC filing metadata
- accession: 0001787306-25-000096
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730625000096/0001787306-25-000096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730625000096/arqt-20250612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-25-000096
- JSON: https://secwatch.observer/filing/0001787306-25-000096.json
- Plain text: https://secwatch.observer/filing/0001787306-25-000096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.